SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Looney RJ, Anolik J, Sanz I. B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells. Lupus 2004; 13: 38190.
  • 2
    Looney RJ, Anolik J, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol 2004; 16: 1805.
  • 3
    Looney RJ. B cell-targeted therapy for rheumatoid arthritis: an update on the evidence. Drugs 2006; 66: 62539.
  • 4
    Looney RJ. Discovering that B cells are important in rheumatoid arthritis. J Rheumatol 2005; 32: 20679.
  • 5
    Looney RJ. Treating human autoimmune disease by depleting B cells. Ann Rheum Dis 2002; 61: 8636.
  • 6
    Looney RJ, Diamond B, Holers M, Lavesque M, Nahm M, St.Clair EW. Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. Clin Immunol 2007; 123: 23543.
  • 7
    Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al, for the DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390400.
  • 8
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793806.
  • 9
    Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 2007; 109: 21829.
  • 10
    Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005; 106: 153843.
  • 11
    Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 43545.
  • 12
    Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 218895.
  • 13
    Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 26876.
  • 14
    Lim SH, Zhang Y, Wang Z, Esler WV, Beggs D, Pruitt B, et al. Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia. Bone Marrow Transplant 2005; 35: 2078.
  • 15
    Miles SA, McGratten M. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma. J Clin Oncol 2005; 23: 2478.
  • 16
    Bermudez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 2000; 85: 8945.
  • 17
    Popa C, Leandro MJ, Cambridge G, Edwards JC. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. Rheumatology (Oxford) 2007; 46: 62630.
  • 18
    Genovese M, Emery P, Ruderman E, Keystone E, Boling E, van Vollenhoven RF, et al. B-cell depletion/repletion patterns, immunoglobulins, and infection rates with repeated rituximab courses [abstract]. Arthritis Rheum 2006; 54 Suppl 9: S77980.
  • 19
    Stiehm E, Ochs H, Winkelstein J. Immunodeficiency disorders? General considerations. In: StiehmER, OchsH, WinkelsteinJ, editors. Immunologic disorders in infants and children. 5th ed. Philadelphia: Elsevier Saunders; 2004.
  • 20
    Looney RJ, Huggins J. Use of intravenous immunoglobulin G (IVIG). Best Pract Res Clin Haematol 2006; 19: 325.
  • 21
    Lack G, Ochs HD, Gelfand EW. Humoral immunity in steroid-dependent children with asthma and hypogammaglobulinemia. J Pediatr 1996; 129: 898903.
  • 22
    Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001; 358: 15113.
  • 23
    Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003; 101: 385761.
  • 24
    Albert D, Khan S, Stansberry J, Kolasinski S, Tsai D, Kamoun M, et al. A phase I trial of rituximab (anti-CD20) for treatment of systemic lupus erythematosus [abstract]. Arthritis Rheum 2004; 50 Suppl 9: S4467.
  • 25
    Gonzalez-Stawinski GV, Yu PB, Love SD, Parker W, Davis RD Jr. Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Clin Immunol 2001; 98: 1759.
  • 26
    Van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002; 100: 22579.
  • 27
    Bearden CM, Agarwal A, Book BK, Vieira CA, Sidner RA, Ochs HD, et al. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transplant 2005; 5: 507.
  • 28
    Albert DA, Moldovan A, Barnack F, Loh L, Eisenberg RA. Response to immunization in SLE patients treated with rituximab [abstract]. Arthritis Rheum 2006; 54 Suppl 9: S550.
  • 29
    Oren C, Mendelbaum M, Paran D, Ablin J, Litinsky I, Levartovsky D, et al. Vaccination against influenza in rheumatoid arthritis patients: the effect of rituximab on the humoral response [abstract]. Arthritis Rheum 2006; 54 Suppl 9: S515.
  • 30
    Vos Q, Lees A, Wu ZQ, Snapper CM, Mond JJ. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev 2000; 176: 15470.
  • 31
    Zandvoort A, Timens W. The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens. Clin Exp Immunol 2002; 130: 411.
  • 32
    Kruetzmann S, Rosado MM, Weber H, Germing U, Tournilhac O, Peter HH, et al. Human immunoglobulin M memory B cells controlling streptococcus pneumoniae infections are generated in the spleen. J Exp Med 2003; 197: 93945.
  • 33
    Isobe Y, Sugimoto K, Shiraki Y, Nishitani M, Koike K, Oshimi K. Successful high-titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab-combined chemotherapy. Am J Hematol 2004; 77: 3703.
  • 34
    Larrar S, Guitton C, Willems M, Bader-Meunier B. Severe hematological side effects following rituximab therapy in children. Haematologica 2006; 91 Suppl 8: ECR36.
  • 35
    Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med 2003; 348: 26914.
  • 36
    Dunleavy K, Hakim F, Kim HK, Janik JE, Grant N, Nakayama T, et al. B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 2005; 106: 795802.
  • 37
    Taylor RP, Lindorfer MA. Drug insight: the mechanism of action of rituximab in autoimmune disease: the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007; 3: 8695.
  • 38
    Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003; 101: 382734.
  • 39
    Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20. Blood 2003; 101: 381826.
  • 40
    Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006; 65: 9839.
  • 41
    Perceau G, Diris N, Estines O, Derancourt C, Levy S, Bernard P. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006; 155: 10536.
  • 42
    Nehring AK, Dua U, Mollee P, Gill D, Grimmett K, Khanna R, et al. Epstein-Barr virus T-cell immunity despite rituximab. Br J Haematol 2007; 136: 62832.
  • 43
    Takei Y, Usui N, Dobashi N, Hagino T, Okawa Y, Takahara S, et al. Progressive outer retinal necrosis in a patient with malignant lymphoma. Rinsho Ketsueki 2004; 45: 2501. In Japanese.
  • 44
    Rituximab (marketed as Rituxan) Information. United States Food and Drug Administration Alert (December 2006). URL: http://www.fda.gov/cder/drug/infopage/rituximab/default.htm.
  • 45
    Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol 2006; 60: 16273.
  • 46
    Berger JR. Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis 2006; 65 Suppl 3: iii4853.
  • 47
    Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab—unforeseen consequences [editorial]. N Engl J Med 2005; 353: 4146.
  • 48
    Steurer M, Clausen J, Gotwald T, Gunsilius E, Stockhammer G, Gastl G, et al. Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab. Transplantation 2003; 76: 4356.
  • 49
    Goldberg SL, Pecora AL, Alter RS, Kroll MS, Rowley SD, Waintraub SE, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002; 99: 14868.
  • 50
    Matteucci P, Magni M, Di Nicola M, Carlo-Stella C, Uberti C, Gianni AM. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody [letter]. Blood 2002; 100: 11045.
  • 51
    Garcia-Suarez J, de Miguel D, Krsnik I, Banas H, Arribas I, Burgaleta C. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 2005; 80: 27181.
  • 52
    Rituxan shows promise in multiple sclerosis trial. Reuters (May 2007). URL: http://www.alertnet.org/thenews/newsdesk/N01237102.htm.
  • 53
    Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006; 180: 6370.
  • 54
    Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease [review]. Arthritis Rheum 2007; 56: 211628.
  • 55
    Edwards JC, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 1999; 97: 18896.
  • 56
    Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001; 40: 20511.
  • 57
    Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005; 44: 15425.
  • 58
    Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006; 54: 297082.
  • 59
    Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007; 56: 126372.
  • 60
    Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005; 52: 316874.
  • 61
    Dunham J, Prak NL, Du YZ, Goodman N, Khan S, Albert D, et al. A longitudinal analysis of SLE patients treated with rituximab: a comparison of B cell depleters to partial B cell depleters [abstract]. Arthritis Rheum 2005; 52 Suppl 9: S740.
  • 62
    Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007; 66: 4705.
  • 63
    Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50: 25809.
  • 64
    Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005; 52: 50113.
  • 65
    Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173: 1807.
  • 66
    Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Rheum 2005; 52: 2628.
  • 67
    Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, van Vollenhoven R, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007; 122: 6274.
  • 68
    Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, Portales-Perez D, Baranda L, Abud-Mendoza C, et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006; 8: R83.
  • 69
    Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colomat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa. Blood 2002; 99: 7548.
  • 70
    Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 39407.
  • 71
    Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, et al. The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48: 4559.
  • 72
    Smolen JS, Keystone EC, Emery P, Breedveld FC, Betteridge N, Burmester GR, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 14350.
  • 73
    Calabrese LH, Zein N. Biologic agents and liver toxicity: an added concern or therapeutic opportunity? Nat Clin Pract Rheumatol 2007; 3: 4223.